Objective: Above-knee amputations (AKAs) and below-knee amputations (BKAs) are associated with high postoperative mortality rates. In this study, we examined factors associated with 30-day, 90-day, and 1-year mortality in patients who underwent a major lower extremity amputation.
During the past 20 years, the rate of major lower extremity amputations (LEA) has been decreasing. There were 196 amputations per 100,000 patients in 1996 and only 119 amputations per 100,000 patients in 2011; a 45% decrease over that time span, possibly attributable to an increase in the number of diagnostic and therapeutic endovascular procedures, improved medical therapy, and earlier disease recognition and treatment. 1 Despite the decrease in numbers, mortality associated with LEA is high and has remained unchanged. The 30-day mortality generally ranges from 9% to 13.5% 2, 3 and has been reported to be higher in some smaller cohort studies. 4 Mortality is reported as 48% at 1 year and 71% at 3 years. 3 Large-scale studies based on national data have examined predictors of short-and long-term mortality in LEA patients, and results have suggested that patients with cardiovascular risk factors, such as coronary artery disease (CAD), end-stage renal disease (ESRD), and increased age, were at higher risk for postoperative mortality. 2, [5] [6] [7] By examining the risk factors in a large-scale, single-center study, we are able to validate previously published results in our patient population and look at factors not available in national databases, such as Bainbridge Ave MAP 4, Bronx, NY 10467 (e-mail: kgarg@montefiore.org).
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indication for amputation. Thirty-day mortality has conventionally been used to describe perioperative mortality. Owing to the large discrepancy between 30-day and 1-year mortality, extending follow-up to 90 days is justified to identify other possible factors that affect mortality.
Statin therapy has shown a number of benefits in patients with vascular disease. [8] [9] [10] Multiple studies have
shown that statin use is associated with lower rates of LEA. 11, 12 No association between statin therapy and mortality has been shown in LEA patients. In 2013 the American College of Cardiology (ACC) and the American Heart Association (AHA) released guidelines on the "Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults." 13 These recommendations divided statin therapy into low-intensity (LIST), medium-intensity (MIST), and high-intensity (HIST) categories and included indications for each category. Despite this, statin therapy is still evaluated in a dichotomized fashion; that is, either "on statin" or "not on statin." This study evaluated 30-and 90-day mortality in patients who underwent LEA by using a single-center cohort to define predictors of mortality over these intervals. We also specifically evaluated the association between statin therapy and 30-day, 90-day, and 1-year mortality based on intensity according to the 2013 ACC/ AHA guidelines. Change in statin therapy regimen in the year after LEA was also investigated.
METHODS
We retrospectively queried a prospectively collected institutional database for all patients who underwent LEA between 2009 and 2014. The Montefiore Medical Center Institutional Review Board approved this research protocol, and patient consent was not required. Patients in both cohorts were selected using Current Procedural Terminology (CPT) codes (American Medical Association, Chicago, Ill) during admission. The major amputations included were below-knee (transtibial; CPT codes: 27880, 27881, and 27882) and above-knee (transfemoral; CPT codes: 27590, 27591, and 27592) amputation.
The index procedure was the first amputation between 2009 and 2014. Staged procedures were evaluated from the time of amputation. Categoric variables evaluated included race, sex, laterality, primary language, CAD, chronic kidney disease (CKD), ESRD requiring hemodialysis (HD), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), diabetes, hypertension, peripheral arterial disease (PAD), indication for amputation (gangrene, nonhealing ulcer, rest pain with nonreconstructable arterial disease, and infection), prior major amputation, admission from nursing home, American Society of Anesthesiologists (ASA) Physical Status Classification, emergency case, staged (guillotine) procedure, perioperative troponin levels, previous open revascularization, occluded bypass graft, statin use, and b-blocker use. Continuous variables evaluated included age and body mass index. CAD was defined as prior diagnosis or prior coronary revascularization. PAD was defined as prior diagnosis or prior lower-extremity revascularization. COPD was noted when there was a prior diagnosis of an obstructive pulmonary process or medical therapy for such. Diabetes was defined as prior diagnosis or medical treatment of diabetes. CHF and CKD were defined as prior diagnosis. ESRD was defined as patients with renal failure requiring chronic renal replacement therapy. Race, language, and indication for amputation were dichotomized for univariate and multivariate analysis.
Stepwise logistic regression analyses were used to estimate the effects of preoperative risk variables on 30-and 90-day mortality. The univariate association between each candidate predictor variable and 30-and 90-day postoperative mortality was examined by using c 2 tests for categoric variables and t-tests for continuous variables. P < .05 was considered significant. The criterion for adding and removing predictors from the model was P < .20. To incorporate potential confounding variables for statin use with mortality, factors with a significant association with statin usage were also incorporated into the multivariate logistic regression. Model discrimination was measured by the area under the receiver operating characteristic curve (concordance): values of 0.5 indicate no discrimination between observed and predicted outcomes, with 1.0 indicating perfect concordance of predicted and observed outcomes. The threshold for reasonable model discrimination was 0.7. The variance inflation factor was calculated to evaluate for multicollinearity for the factors in the final multivariable logistic regressions. A variance inflation factor of $2 was considered criterion for removing a factor from the final model. Estimation of 1-year survival was done by Kaplan-Meier analysis. The log-rank test was used for comparisons. Predictors of 1-year mortality were determined using a stepwise Cox regression model. Take Home Message: In a group of 811 patients 90 day mortality was 24.3% after above-knee amputation and 9.45% after below-knee amputation. Among other factors, medium-intensity and highintensity statin therapies were associated with a mortality benefit at 1 year.
ARTICLE HIGHLIGHTS
The authors recommend aggressive risk factor management in patients undergoing major amputations, with close attention to antilipid therapy.
The statin type and dose was recorded at admission. Prescriptions for statins were recorded up to 1 year after amputation. Indication for HIST and MIST were assessed based on the 2013 ACC/AHA guidelines. 13 Indications for HIST included clinical atherosclerotic cardiovascular disease (ASCVD) in patients aged <75 years, diabetes in patients aged between 45 and 75 years, and a lowdensity lipoprotein level of >190 mg/dL. Although diabetes in a patient between the ages of 45 and 75 is only an indication for HIST in patients with an increased risk of ASCVD, it was categorized as an indication for HIST in this study due to improved primary and secondary prevention in those with diabetes, along with evidence that HIST reduces ASCVD events more than MIST. 13 There is some evidence suggesting that benefit from statin therapy may not be achievable in patients with ESRD on HD and New York Heart Association Functional Classification II to IV heart failure. Because the guidelines specifically made no recommendation regarding the initiation or discontinuation of statins in these patients, we did not exclude these patients from the analysis, and these factors were not taken into account when determining the appropriateness of statin dosing. Statin prescriptions given in the year after the index amputation after the publication of the ACC/AHA guidelines were assessed in context of the guidelines and appropriateness of the prescriptions was determined. Kaplan-Meyer analysis was used to estimate probability of being prescribed appropriate statin therapy after LEA. Data were analyzed with R 
RESULTS
Sample characteristics and mortality rates. We identified 811 patients who underwent an above-knee amputation (AKA) or a below-knee amputation (BKA; Table I ). Of this cohort, 325 patients underwent AKA and 486 patients underwent BKA. Of the BKAs, 102 procedures were staged. The cohort was an average age of 68.8 years (AKA, 74.5; BKA, 64.9; P < .001) and was 53.7% male (AKA, 46.5%; BKA, 58.6%; P < .001). The prevalence of diabetes was high (71.0%) and differed significantly between the AKA and BKA groups: 57.8% and 79.8%, respectively (P < .001). More patients in the BKA group had ESRD on HD (BKA, 20.8%; AKA, 14.4%; P ¼ .028). Patients who were nonambulatory at baseline were more likely to have undergone AKA (BKA, 10.3%; AKA, 20.9%; P < .001). The overall prevalence of CAD was 58.1%, and the overall prevalence of PAD was 44.8%, with no significant differences between the two groups.
The overall 30-day mortality was 8.4% and significantly higher in the AKA group (AKA, 13.5%; BKA, 4.9%; P < .001). The overall 90-day mortality was 15.4% (AKA, 24.3%; BKA, 9.45%; P < .001).
The most common indications for amputation were gangrene, nonhealing ulcer, rest pain with nonreconstructable arterial disease, and soft tissue infection. Other indications included osteomyelitis, nonfunctional joint (Charcot arthropathy), malignancy, and a nonhealing surgical wound. AKAs were more likely to be performed for gangrene (AKA, 64.6%; BKA, 53.3%; P ¼ .002) and rest pain with nonreconstructable arterial disease (AKA, 12.0%; BKA, 7.0%; P ¼ .02). Compared with an AKA, BKAs were more likely to be performed for osteomyelitis (AKA, 1.8%; BKA, 7.6%; P < .001) and nonfunctional joint (AKA, 0.0%; BKA, 2.8%; P < .005). Predictors of overall 30-and 90-day mortality. Univariate analyses for overall 30-and 90-day mortality are presented for all candidate variables in Tables II and III. For 30-day mortality, patients with an AKA had threetimes the odds of dying #30 days, and patients with diabetes had half the odds of 30-day mortality. Multivariate analysis (Table IV) showed that patients undergoing an AKA or an emergency operation had three-times the odds of dying at 30 days. COPD, CKD stage IV, and ESRD on HD conferred increased odds of 30-day mortality. The concordance (C statistic) was 0.76, suggesting reasonable model discrimination. No multicollinearity was detected.
Patients with AKA had three-times the odds of death at 90 days. Admission from a nursing home, ESRD on HD, gangrene as the indication for amputation, and positive perioperative troponin levels all modestly increased the odds of 90-day mortality. Statin therapy, diabetes, and previous open revascularization all decreased the odds of 90-day mortality. The multivariate analysis (Table V) suggested AKA, ESRD on HD, increasing age, and CAD were all significantly associated with death #90 days. Patients on MIST had 58% lower odds of 90-day mortality. There was a trend towards improved 90-day mortality in patients on HIST in the multivariate analysis; the multivariate odds ratio was 0.57 but the finding was not significant (P ¼ .16). The concordance (C statistic) was 0.75, suggesting reasonable model discrimination. No multicollinearity was detected.
Predictors of mortality in the year after LEA. The Kaplan-Meier survival curve for 1-year survival after LEA is shown in Fig 1. The 1-year Results of the Cox proportional hazards model of 1-year survival after major amputation are summarized in Table VI , which includes variables included in the final model. AKA, age >70 years, history of a CABG, gangrene as an indication for LEA, ESRD on HD, COPD, Caucasian race, and having a bilateral amputation as the index procedure were all predictors of mortality in the year after LEA. History of lower extremity bypass was protective against mortality. Being on HIST or MIST at admission was also protective of mortality in the year after LEA. No significant benefit was observed in patients on LIST at admission.
Statin indications based on the 2013 ACC/AHA guidelines and implementation of statin therapy in patients after major amputation. Data collected regarding statin use in this patient population are presented in Table VII . At the time of amputation, 60.5% of all patients were receiving some type of statin therapy, of whom 18.3% were on a HIST, 71.5% were on a MIST, and 10.8% were on a LIST. Patients who underwent a BKA were significantly more likely to be receiving statin therapy (66.9% vs 51.1% in the AKA group). The proportion of patients on HIST, MIST, and LIST did not differ between the AKA and BKA groups. A large number of patients were receiving no statin therapy.
At least 58.7% of the overall cohort had an indication for a HIST, and at least 31.4% of the overall cohort had an indication for a MIST. A higher proportion of the BKA group had an indication for HIST than the AKA group, whereas a higher proportion of the AKA group had an indication for MIST than the BKA group. This is probably related to the age difference in the two groups. We examined statins prescribed in the outpatient setting in the year after amputation after the publication of the 2013 ACC/AHA guidelines, and 191 patients received statin prescriptions #1 year of their amputation. In only 28.3% of these patients was the statin dose congruent with their indication. Appropriate statin therapy was prescribed to 44.7% of patients #1 year of amputation and before death. Fig 2 displays the probability of being prescribed appropriate statin therapy #1 year of LEA.
DISCUSSION
With 811 patients, this study represents the largest single-center experience on major amputations in the past 12 years. The goal of this study was to investigate indications and outcomes after LEA and to thoroughly explore statin use within this population.
The overall 30-day mortality was 8.4%, and was 13.5% for the AKA group and 4.9% for the BKA group. The overall 30-day mortality rate and mortality rate for the AKA group are similar to recently published studies from the Veterans Affairs (VA) system and National Surgical Quality Improvement Program (NSQIP) data. 2, [5] [6] [7] 14 Our data suggest a slightly lower rate of 30-day mortality in the BKA group, which may be due to the exceptionally high prevalence of diabetes in our population. Although diabetes is associated with a higher rate of LEA, 15 studies have shown that diabetic patients have a lower rate of postoperative mortality after LEA. 2, 16, 17 Cohorts with higher proportions of diabetes have reported lowerthan-average 30-day mortality in BKA patients. 18 Studies examining indications for LEA are limited. In our study, critical limb ischemia was present in 77.1% of the overall cohort. Tissue loss was present in 88.3% of these patients, and rest pain was present in 11.7%. The proportion of tissue loss was higher in this cohort than in other previously published studies. 19, 20 Nonhealing surgical wounds reflects nonhealing transmetatarsal or toe amputations that required a LEA. Malignancy as an indication represented a negligible proportion of the cohort. Another major indication for amputation, severe trauma, is not reflected in these results, as our institution is not a level I trauma center. The predictors of 30-and 90-day mortality are consistent with factors identified in previous studies that examined 30-day mortality in LEA patients, consisting mostly of cardiovascular risk factors. 2, 5, 6, 16, 17 This study, however, did not result in as long of a list of factors significantly associated with mortality. Large studies drawing from VA or NSQIP data generally include 4000 to 7000 patients. With only 812 patients, this study failed to detect modifiers with a smaller effect. The 1-year mortality for this cohort was w73%, which is similar to previously reported studies. 5, 6 Predictors of 1-year mortality were similar to the aforementioned predictors of short-term mortality. An AKA or bilateral amputations as the index procedure had the greatest long-term effect on mortality. An important observation is the large number of deaths that occur in this cohort between 30 and 90 days. As shown by the survival curve in Fig 1 and the numbers reported in Table I , approximately the same number of patients die between days 30 and 90 as do between days 0 and 30 before the mortality rate plateaus. Thirty-day mortality is generally perceived as the mortality associated with a given procedure. Amputations, however, impose a significant barrier to mobility, quality of life, and health maintenance that certainly contributed to mortality but may not be observed in the first 30 days after LEA. A recent Cochrane Review 21 found that statin therapy reduced all-cause mortality, cardiovascular disease, CAD, stroke, and the rate of coronary revascularization.
Statin use should have a significant benefit in the LEA population. Much to be expected in this population, statin therapy showed a significant benefit at 90 days and 1 year after LEA. When broken down by intensity, benefit was observed in patients prescribed MIST or HIST at 1 year after LEA. Benefit was also observed in patients prescribed MIST at 90 days after LEA, and there was a trend toward lower mortality in patients prescribed HIST. This result, however, did not reach significance, most likely because only w11% of the cohort was on HIST at admission. No benefit was observed in patients on LIST. According to the AHA guidelines, the only indication for LIST is intolerance to MIST or HIST. 13 Approximately 10% of the cohort was on LIST at the time of amputation. The proportion of vascular patients receiving statin therapy varies greatly within the literature, ranging from 40% to 80%. 22, 23 Given the significant benefits of statin therapy shown in this study and previously published studies, the prevalence of statin therapy, and rate of statin initiation in this population are disappointing: only 60.5% of patients are taking a statin at admission. This number becomes more disappointing when applying parameters set by the ACC/AHA guidelines:
Kaplan-Meier curve shows the probability of appropriate statin therapy being prescribed #1 year after amputation. The shaded area indicates the 95% confidence interval (CI).
only 28.3% of patients are receiving appropriate statin therapy at admission and only 44.7% at 1 year after LEA. Initiation of medical therapy as an inpatient may be an advantageous option for this patient population because adherence after discharge has been shown to be high in other populations. 24 One reason certain patients might not be on statin therapy is that the guidelines specifically made no recommendation regarding the initiation or discontinuation of statins in patients with New York Heart Association class II to IV heart failure or ESRD on HD; this cannot be the explanation in this population, however, because CHF and ESRD on HD were both positively associated with statin use on admission. Although this is certainly a gap in care that needs to be addressed in our population, we saw no benefit in patients who were on appropriate statin therapy at the time of amputation, based on their indications. In our opinion, patients who have a disease process severe enough to warrant an amputation would probably benefit from MIST or HIST.
Appropriate statin therapy is a marker for good primary care, and one might conclude that statin use is confounded by quality primary care in this study. Although identifying all potential confounding variables is impossible, other markers of quality primary care were controlled for in the multivariate analysis. LIST would also be expected to confer a mortality benefit if statin use was actually confounded by quality primary care. One of the important limitations of this study was the lack of data regarding cause of death and postoperative complications. Most predictors of postoperative mortality coincide with predictors of cardiovascular events, but whether these patients are dying from postoperative complications or complications related to their comorbidities but unrelated to surgery is unclear.
Another limitation was the lack of data regarding patient compliance and how often patients took their medication as prescribed. We were also unable to obtain data regarding statin intolerance.
The major limitation of this study, however, is that it is retrospective in nature. Claiming that any single factor can predict mortality would be incorrect because identifying all potential confounding variables is impossible.
LEA patients are a vulnerable population owing to their multiple comorbidities, poor functional status, and social situations that require a high level of care to achieve outstanding outcomes. Unfortunately, most of the research published on this patient population, including this one, focuses solely on medical comorbidities. Our field is limited by a paucity of data on other factors that affect outcomes in this population, such as prosthesis fitting and use, ambulatory status, and living situation. Our group specifically tried to obtain data on prosthesis use but could not identify a reliable source. Further studies should aim to identify important factors auxiliary to medial comorbidities in order to best serve this patient population.
CONCLUSIONS
We have shown that the previously published series using VA and NSQIP data are applicable to our own patients who undergo LEA. We have also presented indications and perioperative mortality for major amputation in our population and identified a major gap in medical management. Although recent technologic advances have decreased the number of amputations during the past 20 years, LEA still poses a significant morbidity and mortality burden on the health care system. Given the benefit of statins shown in this study and numerous other studies, we have identified a significant gap in patient care by establishing that LEA patients are often not on statin and, if they are, are often not on an indicated regimen. Appropriate medical management may play a role in reducing the morbidity and mortality burden of LEA. 
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